FXYD7 Inhibitors
FXYD7 Inhibitors encompass a range of compounds that exert their effects by targeting the Na⁺/K⁺-ATPase pump and related ion transport systems, which FXYD7 is known to modulate. Cardiotonic steroids like ouabain and digoxin bind directly to the Na⁺/K⁺-ATPase pump, a target that FXYD7 closely associates with to exert its modulatory effects. By binding to the pump, these steroids inhibit its activity, which would in turn inhibit the modulatory role of FXYD7. The result is a decreased ability of FXYD7 to influence the pump's kinetics and ion affinity, which is critical for maintaining cellular ion homeostasis.
Additionally, diuretics such as phenamil, triamterene, and amiloride, which inhibit Na⁺ channels, can indirectly lessen the functional demand on the Na⁺/K⁺-ATPase pump. This decreased demand can inhibit the functional modulation by FXYD7 on the enzyme. Aldosterone antagonists such as canrenone, eplerenone, and spironolactone, by reducing the expression of Na⁺/K⁺-ATPase, indirectly inhibit FXYD7's role as a modulatory subunit. Furthermore, loop diuretics like bumetanide, furosemide, and torasemide disrupt the ionic gradient by blocking the Na⁺-K⁺-2Cl⁻ cotransporter, which in turn could decrease the pump's activity and therefore the activity of FXYD7. Lastly, hydrochlorothiazide acts on the Na⁺-Cl⁻ cotransporter, potentially leading to a reduced requirement for Na⁺/K⁺-ATPase activity and indirectly decreasing FXYD7 function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ouabain-d3 (Major) | sc-478417 | 1 mg | $516.00 | |||
A cardiotonic steroid that specifically inhibits the Na⁺/K⁺-ATPase pump. Since FXYD7 modulates Na⁺/K⁺-ATPase activity, ouabain binding to the pump could inhibit its modulation by FXYD7, leading to reduced FXYD7 activity. | ||||||
12β-Hydroxydigitoxin | 20830-75-5 | sc-213604 sc-213604A | 1 g 5 g | $143.00 $694.00 | ||
12β-Hydroxydigitoxin binding can hinder the association of FXYD7 with the pump, thereby inhibiting the functional activity of FXYD7. | ||||||
Triamterene | 396-01-0 | sc-213103A sc-213103 | 1 g 5 g | $22.00 $54.00 | ||
A potassium-sparing diuretic that blocks Na⁺ channels. This reduction in Na⁺ flow can lessen the activity of Na⁺/K⁺-ATPase, which may reduce the modulatory effect of FXYD7 on this pump. | ||||||
Eplerenone | 107724-20-9 | sc-203943 sc-203943A | 10 mg 50 mg | $110.00 $624.00 | 4 | |
A selective aldosterone blocker that, by reducing Na⁺/K⁺-ATPase expression, can indirectly reduce FXYD7 modulation of this enzyme. | ||||||
Amiloride • HCl | 2016-88-8 | sc-3578 sc-3578A | 25 mg 100 mg | $22.00 $57.00 | 6 | |
A diuretic that inhibits epithelial Na⁺ channels. By decreasing Na⁺ reabsorption, amiloride indirectly reduces the functional demand on Na⁺/K⁺-ATPase, potentially diminishing FXYD7 activity. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
An aldosterone antagonist that can decrease Na⁺/K⁺-ATPase expression and thus indirectly reduce the functional modulation of this enzyme by FXYD7. | ||||||
Bumetanide (Ro 10-6338) | 28395-03-1 | sc-200727 sc-200727A | 1 g 5 g | $109.00 $228.00 | 9 | |
A loop diuretic that inhibits the Na⁺-K⁺-2Cl⁻ cotransporter. By altering the ionic gradient, bumetanide may indirectly reduce Na⁺/K⁺-ATPase activity, affecting FXYD7 modulation. | ||||||
Furosemide | 54-31-9 | sc-203961 | 50 mg | $41.00 | ||
A loop diuretic that blocks the Na⁺-K⁺-2Cl⁻ cotransporter. By altering the activity of Na⁺/K⁺-ATPase, furosemide may indirectly influence FXYD7's modulatory role. | ||||||
Torsemide | 56211-40-6 | sc-213059 | 10 mg | $260.00 | ||
A diuretic that inhibits the Na⁺-K⁺-2Cl⁻ cotransporter. It can diminish Na⁺/K⁺-ATPase activity, thereby indirectly affecting the modulation by FXYD7. | ||||||
Hydrochlorothiazide | 58-93-5 | sc-207738 sc-207738A sc-207738B sc-207738C sc-207738D | 5 g 25 g 50 g 100 g 250 g | $55.00 $240.00 $333.00 $562.00 $988.00 | ||
A thiazide diuretic that inhibits the Na⁺-Cl⁻ cotransporter. This can lead to a reduced requirement for Na⁺/K⁺-ATPase activity and thus decrease FXYD7 activity. | ||||||